Cover Image
市場調查報告書

抗真菌劑的全球市場的未來預測

GLOBAL ANTIFUNGAL DRUGS MARKET FORECAST 2017-2025

出版商 Inkwood Research 商品編碼 481376
出版日期 內容資訊 英文 148 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
抗真菌劑的全球市場的未來預測 GLOBAL ANTIFUNGAL DRUGS MARKET FORECAST 2017-2025
出版日期: 2017年09月01日 內容資訊: 英文 148 Pages
簡介

本報告提供全球抗真菌劑市場未來展望相關分析,主要的推動及阻礙市場要素,及整體市場規模趨勢預測 (今後9年份),各產品種類、各疾病、各用途及各地區詳細趨勢,市場競爭環境及向心力,各國政府的相關法規、政策,主要企業簡介等調查。

第1章 分析範圍

第2章 分析方法

第3章 摘要整理

第4章 市場動態

  • 推動市場要素
  • 阻礙市場要素
  • 市場機會
  • 課題

第5章 市場區隔

  • 藥物的各類型
    • Echinocandins市場
    • Azole市場
    • Polyenes市場
    • 丙烯基胺市場
    • 其他市場
  • 治療對象的各症狀
    • 麴菌症
    • 念珠菌症
    • 其他
  • 各用途
    • 局部抗真菌劑
    • 口服藥

第6章 主要分析指標

  • 波特的五力分析
    • 新加入企業的威脅
    • 替代產品/服務的威脅
    • 買主談判力
    • 供應商談判力
    • 企業間競爭的強度
  • PESTEL分析
  • 主要的購買標準
  • 價值鏈分析
  • 策略建議
  • 結論
  • 市場機會矩陣
  • 供應商環境

第7章 地區分析

  • 北美市場 (美國,加拿大)
  • 歐洲市場 (英國,法國,德國,西班牙,義大利等)
  • 亞太地區市場 (印度,中國,日本等)
  • 其他的國家 (RoW)的市場 (南美,中東、北非,非洲)

第8章 競爭環境

  • 市場佔有率分析
  • 主要市場競爭策略

第9章 企業簡介

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: 4466

KEY FINDINGS

The global antifungal drugs market is projected to develop from $12567 million in 2016 to $17428 million by 2025. Increasing awareness of the various fungal infections amid people is the prime factor up surging the antifungal drugs market globally. The market is anticipated to grow with 3.70% of CAGR throughout the forecasting period.

MARKET INSIGHTS

The antifungal drugs market is segmented on the basis of drug types, therapeutic indications, applications, and geography. The antifungal drugs market on the basis of drug types is segmented into echinocandins, azoles, polyenes, allylamines, and others. On the basis of therapeutic indications, aspergillosis, dermatophytosis, candidiasis, and others. The antifungal drugs market by application is segregated into topical antifungal drugs and oral drugs. The antifungal drugs market on the basis of geography is segmented into Asia-Pacific, Europe, Rest of the World and North America.

Lack of hygiene, healthcare policies and programs by the government, and advancement of drug resistance are the major drivers developing the antifungal drugs market.

REGIONAL INSIGHTS

North America antifungal drugs market possesses the colossal market share in the global antifungal drugs market in 2016. A large number of people suffering from fungal infection and advancement in antifungal biopharmaceuticals in the region is up surging the growth of the antifungal market. The Asia-Pacific region is projected to be the fastest-growing region for the global antifungal drugs market. The Europe antifungal drugs market is estimated to grow during the forecast period.

COMPETITIVE INSIGHTS

The leading market players for Antifungal drugs market are Vertex Pharmaceuticals, Teva Pharmaceuticals, Sanofi-Aventis, Pfizer, Novartis, Merck & Co, Kramer Laboratories, Johnson & Johnson, GlaxoSmithKline, Gilead, Bayer healthcare, Astellas Pharma Inc., Arbor Pharmaceuticals Inc., Abbott Laboratories, and 3 Baxter.

1. RESEARCH SCOPE

  • 1.1. STUDY GOALS
  • 1.2. SCOPE OF THE MARKET STUDY
  • 1.3. WHO WILL FIND THIS REPORT USEFUL?
  • 1.4. STUDY AND FORECASTING YEARS

2. RESEARCH METHODOLOGY

  • 2.1. SOURCES OF DATA
    • 2.1.1. SECONDARY DATA
    • 2.1.2. PRIMARY DATA
  • 2.2. TOP DOWN APPROACH
  • 2.3. BOTTOM-UP APPROACH
  • 2.4. DATA TRIANGULATION
  • 2.5. ESTIMATION METHODOLOGY

3. EXECUTIVE SUMMARY

  • 3.1. MARKET DEFINITION AND SCOPE
  • 3.2. KEY FINDINGS

4. MARKET DYNAMICS

  • 4.1. DRIVERS
    • 4.1.1. POOR HYGIENE HABITS
    • 4.1.2. DEVELOPMENT OF DRUG RESISTANCE
    • 4.1.3. HEALTHCARE POLICIES AND PROGRAMS BY GOVERNMENT
  • 4.2. RESTRAINTS
    • 4.2.1. ALTERNATE TREATMENT OPTIONS
    • 4.2.2. REGULATORY ATMOSPHERE
  • 4.3. OPPORTUNITIES
    • 4.3.1. HEALTHCARE AND RELATED INDUSTRIES ARE GROWING CONTINUOUSLY
    • 4.3.2. INCREASING AWARENESS AND AVAILABILITY OF INFORMATION
  • 4.4. CHALLENGES
    • 4.4.1. SIDE EFFECTS AND RECURRING FUNGAL INFECTIONS
    • 4.4.2. RESISTANCE TO DRUGS
    • 4.4.3. RAPIDLY CHANGING TECHNOLOGY

5. MARKET SEGMENTATION

  • 5.1. BY DRUG TYPES
    • 5.1.1. ECHINOCANDINS MARKET
    • 5.1.2. AZOLES MARKET
    • 5.1.3. POLYENES MARKET
    • 5.1.4. ALLYLAMINES MARKET
    • 5.1.5. OTHERS MARKET
  • 5.2. BY THERAPEUTIC INDICATIONS
    • 5.2.1. ASPERGILLOSIS MARKET
    • 5.2.2. DERMATOPHYTOSIS MARKET
    • 5.2.3. CANDIDIASIS MARKET
    • 5.2.4. OTHERS MARKET
  • 5.3. BY APPLICATIONS
    • 5.3.1. TOPICAL ANTIFUNGAL DRUGS MARKET
    • 5.3.2. ORAL DRUGS MARKET

6. KEY ANALYTICS

  • 6.1. PORTER'S FIVE FORCE MODEL
    • 6.1.1. THREAT OF NEW ENTRANTS
    • 6.1.2. THREAT OF SUBSTITUTE PRODUCTS OR SERVICES
    • 6.1.3. BARGAINING POWER OF BUYER
    • 6.1.4. BARGAINING POWER OF SUPPLIER
    • 6.1.5. INTENSITY OF COMPETITIVE RIVALRY
  • 6.2. PESTEL ANALYSIS
  • 6.3. KEY BUYING CRITERIA
  • 6.4. VALUE CHAIN ANALYSIS
  • 6.5. STRATEGIC RECOMMENDATION
  • 6.6. STRATEGIC CONCLUSIONS
  • 6.7. OPPORTUNITY MATRIX
  • 6.8. VENDOR LANDSCAPE

7. GEOGRAPHICAL ANALYSIS

  • 7.1. NORTH AMERICA ANTIFUNGAL DRUGS MARKET 2017-2025 ($ MILLION)
    • 7.1.1. UNITED STATES (U.S.) ANTIFUNGAL DRUGS MARKET
    • 7.1.2. CANADA ANTIFUNGAL DRUGS MARKET
  • 7.2. EUROPE ANTIFUNGAL DRUGS MARKET
    • 7.2.1. UNITED KINGDOM (UK) ANTIFUNGAL DRUGS MARKET
    • 7.2.2. FRANCE ANTIFUNGAL DRUGS MARKET
    • 7.2.3. GERMANY ANTIFUNGAL DRUGS MARKET
    • 7.2.4. SPAIN ANTIFUNGAL DRUGS MARKET
    • 7.2.5. ITALY ANTIFUNGAL DRUGS MARKET
    • 7.2.6. ROE ANTIFUNGAL DRUGS MARKET
  • 7.3. ASIA PACIFIC ANTIFUNGAL DRUGS MARKET
    • 7.3.1. INDIA ANTIFUNGAL DRUGS MARKET
    • 7.3.2. CHINA ANTIFUNGAL DRUGS MARKET
    • 7.3.3. JAPAN ANTIFUNGAL DRUGS MARKET
    • 7.3.4. ROAPAC ANTIFUNGAL DRUGS MARKET
  • 7.4. REST OF THE WORLD ANTIFUNGAL DRUGS MARKET
    • 7.4.1. LATIN AMERICA ANTIFUNGAL DRUGS MARKET
    • 7.4.2. MENA ANTIFUNGAL DRUGS MARKET
    • 7.4.3. AFRICA ANTIFUNGAL DRUGS MARKET

8. COMPETITIVE LANDSCAPE

  • 8.1. MARKET SHARE ANALYSIS
  • 8.2. TOP WINNING STRATEGIES

9. COMPANY PROFILES

  • 9.1. ABBOTT LABORATORIES.
    • 9.1.1. OVERVIEW
    • 9.1.2. PRODUCT PORTFOLIO
    • 9.1.3. SCOT ANALYSIS
    • 9.1.4. STRATEGIC INITIATIVES
  • 9.2. ARBOR PHARMACEUTICALS, INC.
    • 9.2.1. OVERVIEW
    • 9.2.2. PRODUCT PORTFOLIO
    • 9.2.3. SCOT ANALYSIS
    • 9.2.4. STRATEGIC INITIATIVES
  • 9.3. BAXTER
    • 9.3.1. OVERVIEW
    • 9.3.2. PRODUCT PORTFOLIO
    • 9.3.3. SCOT ANALYSIS
    • 9.3.4. STRATEGIC INITIATIVES
  • 9.4. ASTELLAS PHARMA INC.
    • 9.4.1. OVERVIEW
    • 9.4.2. PRODUCT PORTFOLIO
    • 9.4.3. SCOT ANALYSIS
    • 9.4.4. STRATEGIC INITIATIVES
  • 9.5. BAYER HEALTHCARE
    • 9.5.1. OVERVIEW
    • 9.5.2. PRODUCT PORTFOLIO
    • 9.5.3. SCOT ANALYSIS
    • 9.5.4. STRATEGIC INITIATIVE
  • 9.6. TEVA PHARMACEUTICALS
    • 9.6.1. OVERVIEW
    • 9.6.2. PRODUCT PORTFOLIO
    • 9.6.3. SCOT ANALYSIS
    • 9.6.4. STRATEGIC INITIATIVES
  • 9.7. GILEAD
    • 9.7.1. OVERVIEW
    • 9.7.2. PRODUCT PORTFOLIO
    • 9.7.3. SCOT ANALYSIS
    • 9.7.4. STRATEGIC INITIATIVES
  • 9.8. GLAXOSMITHKLINE
    • 9.8.1. OVERVIEW
    • 9.8.2. PRODUCT PORTFOLIO
    • 9.8.3. SCOT ANALYSIS
    • 9.8.4. STRATEGIC MOVES
  • 9.9. JOHNSON & JOHNSON
    • 9.9.1. OVERVIEW
    • 9.9.2. PRODUCT PORTFOLIO
    • 9.9.3. SCOT ANALYSIS
    • 9.9.4. STRATEGIC MOVES
  • 9.10. KRAMER LABORATORIES
    • 9.10.1. OVERVIEW
    • 9.10.2. PRODUCT PORTFOLIO
    • 9.10.3. SCOT ANALYSIS
  • 9.11. MERCK & CO.
    • 9.11.1. OVERVIEW
    • 9.11.2. PRODUCT PORTFOLIO
    • 9.11.3. SCOT ANALYSIS
    • 9.11.4. STRATEGIC MOVES
  • 9.12. NOVARTIS
    • 9.12.1. OVERVIEW
    • 9.12.2. PRODUCT PORTFOLIO
    • 9.12.3. SCOT ANALYSIS
    • 9.12.4. STRATEGIC MOVES
  • 9.13. PFIZER
    • 9.13.1. OVERVIEW
    • 9.13.2. PRODUCT PORTFOLIO
    • 9.13.3. SCOT ANALYSIS
    • 9.13.4. STRATEGIC MOVES
  • 9.14. SANOFI-AVENTIS
    • 9.14.1. OVERVIEW
    • 9.14.2. PRODUCT PORTFOLIO
    • 9.14.3. SCOT ANALYSIS
    • 9.14.4. STRATEGIC INITIATIVE
  • 9.15. VERTEX PHARMACEUTICALS
    • 9.15.1. OVERVIEW
    • 9.15.2. PRODUCT PORTFOLIO
    • 9.15.3. SCOT ANALYSIS
    • 9.15.4. STRATEGIC INITIATIVE

TABLE LIST

  • TABLE 1 GLOBAL ANTIFUNGAL DRUGS MARKET BY GEOGRAPHY 2017-2025 ($MILLION)
  • TABLE 2 GLOBAL ANTIFUNGAL DRUGS MARKET BY DRUG TYPES 2017-2025 ($ MILLION)
  • TABLE 3 INDICATION AND DOSES OF ECHINOCANDIN
  • TABLE 4 GLOBAL ECHINOCANDINS MARKET BY GEOGRAPHY 2017-2025 ($ MILLION)
  • TABLE 5 DRUG USES OF TRIAZOLES
  • TABLE 6 GLOBAL AZOLES MARKET BY GEOGRAPHY 2017-2025 ($ MILLION)
  • TABLE 7 GLOBAL POLYENES MARKET BY GEOGRAPHY 2017-2025 ($ MILLION)
  • TABLE 8 PRICE OF ALLYLAMINE ANTIFUNGALS
  • TABLE 9 GLOBAL ALLYLAMINES MARKET BY GEOGRAPHY 2017-2025 ($ MILLION)
  • TABLE 10 GLOBAL ANTIFUNGAL DRUGS MARKET BY THERAPEUTIC INDICATIONS MARKET 2017-2025 ($ MILLION)
  • TABLE 11 GLOBAL ASPERGILLOSIS MARKET BY GEOGRAPHY 2017-2025 ($ MILLION)
  • TABLE 12 COMMON AFFECTED AREA - DERMATOPHYTES
  • TABLE 13 GLOBAL DERMATOPHYTOSIS MARKET BY GEOGRAPHY 2017-2025 ($ MILLION)
  • TABLE 14 SYMPTOMS IN THE AFFECTED AREA CAUSED BY CANDIDIASIS
  • TABLE 15 GLOBAL CANDIDIASIS MARKET BY GEOGRAPHY 2017-2025 ($ MILLION)
  • TABLE 16 GLOBAL OTHERS MARKET BY GEOGRAPHY 2017-2025 ($ MILLION)
  • TABLE 17 GLOBAL ANTIFUNGAL DRUGS MARKET BY APPLICATIONS MARKET 2017-2025 ($ MILLION)
  • TABLE 18 PROS AND CONS OF TOPICAL MEDICATIONS
  • TABLE 19 BRANDS OF ANTIFUNGAL POWDERS AND THEIR FUNCTIONALITY
  • TABLE 20 BRANDS OF ANTIFUNGAL OINTMENTS AND THEIR FUNCTIONALITY
  • TABLE 21 ANTIFUNGAL PASTES AND ITS EFFECT
  • TABLE 22 COMMONLY USED ANTIFUNGAL DRUGS DOSAGE AND ITS EFFECTS
  • TABLE 23 GLOBAL ANTIFUNGAL DRUGS MARKET BY GEOGRAPHY 2017-2025 ($ MILLION)
  • TABLE 24 NORTH AMERICA ANTIFUNGAL DRUGS MARKET BY REGION 2017-2025 ($ MILLION)
  • TABLE 25 EUROPE ANTIFUNGAL DRUGS MARKET 2017-2025 ($ MILLION)
  • TABLE 26 FINAL CONSUMPTION OF MEDICAL GOODS AND SERVICES BY HOUSEHOLD
  • TABLE 27 TOTAL BURDEN OF FUNGAL INFECTIONS IN SPAIN 2015
  • TABLE 28 ASIA PACIFIC ANTIFUNGAL DRUGS MARKET BY REGION 2017-2025 ($ MILLION)
  • TABLE 29 INDIA'S HEALTHCARE SECTOR INVESTMENT
  • TABLE 30 COMPANIES IN CHINA PRODUCING ANTIFUNGAL DRUGS
  • TABLE 31 TOTAL BURDEN OF FUNGAL INFECTIONS IN JAPAN
  • TABLE 32 REST OF THE WORLD ANTIFUNGAL DRUGS MARKET BY REGION 2017-2025 ($ MILLION)
  • FIGURES LIST
  • FIGURE 1 GLOBAL ANTIFUNGAL DRUGS MARKET 2017-2025 ($MILLION)
  • FIGURE 2 HEALTHCARE PROGRAMS INITIATED BY THE INDIAN GOVERNMENT
  • FIGURE 3 ALTERNATIVE MEDICINE IN THE US (IN MILLION US DOLLARS)
  • FIGURE 4 HEALTHCARE INDUSTRY IN THE WORLD IS RAPIDLY GROWING (%)
  • FIGURE 5 GLOBAL ECHINOCANDINS MARKET 2017-2025 ($ MILLION)
  • FIGURE 6 GLOBAL AZOLES MARKET 2017-2025 ($ MILLION)
  • FIGURE 7 GLOBAL POLYENES MARKET 2017-2025 ($ MILLION)
  • FIGURE 8 GLOBAL ALLYLAMINES MARKET 2017-2025 ($ MILLION)
  • FIGURE 9 GLOBAL OTHERS MARKET 2017-2025 ($ MILLION)
  • FIGURE 10 GLOBAL OTHERS MARKET BY GEOGRAPHY 2017-2025 ($ MILLION)
  • FIGURE 11 GLOBAL ASPERGILLOSIS MARKET 2017-2025 ($ MILLION)
  • FIGURE 12 GLOBAL DERMATOPHYTOSIS MARKET 2017-2025 ($ MILLION)
  • FIGURE 13 GLOBAL CANDIDIASIS MARKET 2017-2025 ($ MILLION)
  • FIGURE 14 GLOBAL OTHERS MARKET 2017-2025 ($ MILLION)
  • FIGURE 15 TOPICAL ANTIFUNGAL DRUGS TYPES
  • FIGURE 16 GLOBAL TOPICAL ANTIFUNGAL DRUGS MARKET 2017-2025 ($ MILLION)
  • FIGURE 17 GLOBAL TOPICAL ANTIFUNGAL DRUGS MARKET BY GEOGRAPHY 2017-2025 ($ MILLION)
  • FIGURE 18 GLOBAL ORAL DRUGS MARKET 2017-2025 ($ MILLION)
  • FIGURE 19 GLOBAL ORAL DRUGS MARKET BY GEOGRAPHY 2017-2025 ($ MILLION)
  • FIGURE 20 PORTER'S FIVE FORCE MODEL IN ANTIFUNGAL DRUGS MARKET
  • FIGURE 21 HEALTHCARE INVESTMENT IN THE U.S. 2012-2015 ($ BILLION)
  • FIGURE 22 ANTIFUNGAL DRUGS MARKET IN THE U.S. 2017-2025 ($ MILLION)
  • FIGURE 23 CANADA ANTIFUNGAL DRUGS MARKET 2017-2025 ($ MILLION)
  • FIGURE 24 PHARMACEUTICAL SALES IN DIFFERENT COUNTRIES IN EUROPE 2014 ($ MILLION)
  • FIGURE 25 HEALTHCARE EXPENDITURE IN UK 2010-2015 (£ BILLION)
  • FIGURE 26 U.K. ANTIFUNGAL DRUGS MARKET 2017-2025 ($MILLION)
  • FIGURE 27 INVESTMENT MADE BY DIFFERENT DRUGS IN FRANCE 2015 (%)
  • FIGURE 28 FRANCE ANTIFUNGAL DRUGS MARKET 2017-2025 ($ MILLION)
  • FIGURE 29 GERMANY ANTIFUNGAL DRUGS MARKET 2017-2025 ($ MILLION)
  • FIGURE 30 SPAIN ANTIFUNGAL DRUGS MARKET 2017-2025 ($ MILLION)
  • FIGURE 31 ITALY ANTIFUNGAL DRUGS MARKET 2017-2025 ($ MILLION)
  • FIGURE 32 ROE ANTIFUNGAL DRUGS MARKET 2017-2025 ($ MILLION)
  • FIGURE 33 PER CAPITA HEALTHCARE EXPENDITURE IN INDIA ($)
  • FIGURE 34 INDIA ANTIFUNGAL DRUGS MARKET 2017-2025 ($ MILLION)
  • FIGURE 35 CHINA ANTIFUNGAL DRUGS MARKET 2017-2025 ($ MILLION)
  • FIGURE 36 JAPAN ANTIFUNGAL DRUGS MARKET 2017-2025 ($ MILLION)
  • FIGURE 37 ROAPAC ANTIFUNGAL DRUGS MARKET 2017-2025 ($ MILLION)
  • FIGURE 38 LATIN AMERICA ANTIFUNGAL DRUGS MARKET 2017-2025 ($ MILLION)
  • FIGURE 39 VARIOUS SECTORS INVESTMENTS IN THE MENA REGION
  • FIGURE 40 MENA ANTIFUNGAL DRUGS MARKET 2017-2025 ($ MILLION)
  • FIGURE 41 AFRICA ANTIFUNGAL DRUGS MARKET 2017-2025 ($ MILLION)
  • FIGURE 42 GLOBAL ANTIFUNGAL DRUGS MARKET SHARE ANALYSIS
Back to Top